Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACKER: Topical rVA576 (Nomacopan) in Atopic and Vernal Keratoconjunctivitis
NCT04037891Phase 2Terminated
- Sponsor
- Akari Therapeutics
- Start
- Mar 2019
- Primary completion
- Apr 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of nomacopan in atopic keratoconjunctivitis (AKC), Vernal Keratoconjunctivitis (VKC) and allergic conjunctivitis (AC) (3 arms), sponsored by Akari Therapeutics. Primary endpoint: Incidence of Ocular Treatment-Emergent Adverse Events at 56 days. Started Mar 2019; status: terminated.
02
Drugs
nomacopan
03
Conditions
atopic keratoconjunctivitis (AKC)Vernal Keratoconjunctivitis (VKC)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT04037891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037891.